Oncoinvent ASA (0RU5.L) LSE

43.90

-0.1(-0.23%)

Updated at June 02 10:29AM

Currency In NOK

Oncoinvent ASA

Address

Gullhaugveien 7

Oslo, 0484

Norway

Phone

47 55 96 11 59

Website

https://www.oncoinvent.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

December 13, 2017

Key Executives

Name	Title	Pay	Year Born
Oystein Soug	Chief Executive Officer	4.59M	1969
Ramzi Amri	Chief Financial Officer	1.86M	N/A
Stian Brekke	Head of Regulatory Affairs	1.95M	N/A
Kristine Lofthus	Chief Production Officer	2.1M	N/A
Anne-Kirsti Aksnes	Chief Clinical Officer	2.4M	N/A
Gro Elisabeth Hjellum	Chief Operating Officer	2.82M	N/A
Anne Cecile Alvik	Head of Quality Assurance & Employee Representative Director	2.85M	N/A
Kari Myren	Chief Medical Officer	2.97M	N/A
Kaja Tunhovd Johansen	Head of Quality Control	0	N/A

Description

Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.